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Abstract 
 
Ischemic heart disease is the main cause of death and morbidity in most of the industrialized 
countries.  Stem- and progenitor cell-based treatment approaches for ischemic heart disease 
are therefore an important frontier in cardiovascular and regenerative medicine.  Based on 
experimental studies demonstrating that bone-marrow-derived stem and endothelial 
progenitor cells can improve cardiac function after myocardial infarction, clinical phase I and 
II studies were rapidly initiated to translate this concept into the clinical setting.  However, as 
of now the effects of stem/progenitor cell administration on cardiac function in the clinical 
setting did not meet the expectations.  Thus, a better understanding of causes of the current 
limitations of cell-based therapies is urgently required.  Importantly, the number and function 
of endothelial progenitor cells is reduced in patients with cardiovascular risk factors and/or 
coronary artery disease.  These observations may provide opportunities for an optimization 
of cell-based treatment approaches. 
This review provides a summary of the current evidence for the role and potential of stem 
and progenitor cells in the pathophysiology and treatment of ischemic heart disease, 
including the properties and repair and regenerative capacities of various stem and 
progenitor cell populations.  In addition, we describe modes of stem/progenitor cell delivery, 
modulation of their homing as well as potential approaches to “prime” stem/progenitor cells 
for cardiovascular cell-based therapies. 
 
C. Templin et al. 
 
3 
Introduction 
 
Coronary artery disease, i.e. acute myocardial infarction and ischemic cardiomyopathy, are 
the main causes of death in most of the developed countries and are a major socioeconomic 
healthcare problem (Landmesser et al. 2005).  Despite improved pharmacological therapy 
and coronary revascularization procedures by either percutaneous coronary intervention PCI 
or coronary artery bypass surgery CABG there is still a major need for novel therapeutic 
approaches (Landmesser et al. 2005); (Ford et al. 2007).  Whereas current treatment 
strategies aim largely to limit or delay progression of cardiac dysfunction (Landmesser et al. 
2005; Landmesser et al. 2009; Segers et al. 2008) stimulation of vascular and cardiac repair 
mechanisms, such as those mediated by stem/progenitor cells, has become an important 
focus of cardiovascular research (Landmesser 2009).  In fact, in patients with ischemic heart 
failure it is unlikely that the inhibition of novel neurohormonones other than catecholamines, 
angiotensin and aldosterone will further improve cardiovascular outcome, underlining the 
need for novel therapeutic concepts to promote cardiac repair (Landmesser et al. 2009). 
Experimental and first small- to intermediate scale clinical studies have suggested the 
feasibility and safety of cell-based therapies in patients with ischemic cardiomyopathy 
(Landmesser 2009; Schachinger et al. 2006; Segers et al. 2008).  Heterogeneous cell 
populations have been thoroughly investigated as potential sources of cardiac progenitors in 
cell based therapy for ischemic heart disease.  To date, different autologous adult stem and 
progenitor cells, in particular several subtypes of bone marrow-derived cells, isolated adipose 
tissue-derived or cardiac-derived stem/progenitor cells are under preclinical and clinical 
evaluation.  Additionally, embryonic stem cells and induced pluripotent stem cells provide 
regenerative capacity and improve cardiac function after ischemia in animal models (Nelson 
et al. 2009; van Laake et al. 2008).  In an attempt to update the current field of cell-based 
therapy for ischemic heart disease, this review will discuss: (1) relevant stem and progenitor 
cell populations in myocardial regenerative medicine, (2) routes of cell delivery, (3) current 
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status of clinical trials, (4) mechanisms of adult stem and progenitor cell therapy, (5) 
limitations of current treatment strategies and (6) future developments of cell-based therapy. 
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Overview of cell types for cardiac repair 
 
Over the past decade, early small and intermediate sized clinical trials have examined the 
effects of skeletal myoblasts (Menasche 2008; Menasche et al. 2003), circulating endothelial 
progenitor cells (Assmus et al. 2002; Hirsch et al. 2006), and bone marrow- derived 
mononuclear cell populations (Schachinger et al. 2006; Wollert et al. 2004) for treatment of 
ischemic heart disease.  In addition, several progenitor and stem cell types have been 
studied in animal models to examine their potential use, including embryonic stem cells 
(ESCs) (Laflamme et al. 2007; van Laake et al. 2008), hematopoietic stem cells (HSCs) 
(Murry et al. 2004; Templin et al. 2008), mesenchymal stem cells (MSCs) (Mangi et al. 
2003), endothelial progenitor cells (EPCs) (Aicher et al. 2003; Giannotti et al. 2010; 
Sorrentino et al. 2007), and, most recently, resident cardiac stem cells (CSCs) (Beltrami et 
al. 2003; Laugwitz et al. 2005; Oh et al. 2003).  Each cell types comprise unique profiles 
regarding isolation and culture, cell surface marker expression, transcription factors, 
expressed proteins, and ability to differentiate into other cell types: 
 
Adult stem and progenitor cells 
Bone-marrow-derived and circulating adult stem/progenitor cells:  Stem/progenitor cells 
isolated from the bone marrow, peripheral blood, and other tissues have been used in cell-
based treatments for ischemic heart disease.  In contrast to pluripotent embryonic stem cells, 
adult stem cells display a limited and still controversial transdifferentiation capacity towards 
cardiomyocytes.  The two major subsets of bone marrow-derived stem cells are HSCs and 
MSCs.  The true bone-marrow stem cells comprise <0.01% of the total bone marrow cells 
(Abkowitz et al. 2002; Pittenger et al. 2004) and may be isolated by direct marrow aspiration 
or obtained from peripheral blood after cytokine mobilization.  Compared with other stem cell 
types, these cells appear to be present in greater numbers in vivo and have been studied 
particularly well, at least in part due to the fact that they can be rather easily obtained.  Other 
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multipotent progenitor cells located in the bone marrow include side-population cells, which 
are characterised by their ability to efflux Hoechst dye (Challen et al. 2006). 
Hematopoietic stem/progenitor cells express CD34 and CD133 cell surface antigens and 
have shown the ability to home to injured myocardium, but whether they differentiate into 
cardiomyocytes has been debated (Jackson et al. 2001; Murry et al. 2004). 
 
Mesenchymal stem cells are present in adult tissues including the bone marrow and adipose 
tissue (Tomita et al. 1999).  Criterions for their characterization have recently been 
summarized by a position statement of the international society for cellular therapy and 
include the expression of CD105, CD73 and CD90 and lack of expression of markers such 
as CD34, CD45, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface molecules and 
their ability to differentiate into osteoblasts, adipocytes, and chondroblasts in vitro (Conget et 
al. 1999) (Dominici et al. 2006).  MSCs can be isolated and expanded easily and have been 
suggested to improve left ventricular function after myocardial infarction (Makino et al. 1999; 
Schuleri et al. 2008; Toma et al. 2002) (Mangi et al. 2003).  Furthermore, non-invasive 
multimodality imaging has suggested that therapy after myocardial infarction with allogeneic 
MSCs promotes active cardiac repair in vivo (Amado et al. 2006). 
It has been proposed by experimental in vitro data that adipose tissue–derived MSCs may 
transdifferentiate into cardiomyocyte-like cells and endothelial cells (Planat-Benard et al. 
2004; Planat-Benard et al. 2004).  However, as discussed above, there is no definite proof as 
of today for a complete transdifferentation into cardiomyocytes.  Adipose cells have been 
regarded as an attractive source because they are available in high quantities and easy to 
obtain. 
 
Endothelial progenitor cells comprise a heterogenous circulating cell population likely derived 
largely from the bone marrow (Urbich et al. 2004).  Different types of endothelial progenitor 
cells have been proposed, in particular “early” and “late” EPCs, based on their appearance in 
the culture of circulating mononuclear cells in endothelial medium (Hur et al. 2004).  Early 
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EPCs promote likely endothelial repair (Giannotti et al. 2010) and angiogenesis (Sieveking et 
al. 2008) largely by paracrine effects, whereas late EPCs, that are very low in number, may 
become endothelial cells.  The differentiation potential of early EPCs into cardiomyocytes 
has been questioned (Gruh et al. 2006). 
Endothelial progenitor cells isolated from patients with diabetes or hypertension display a 
reduced activity in promoting re-endothelialization of denuded arteries and blood flow 
recovery after ischemia when transplanted into nude mice (Giannotti et al. 2010; Landmesser 
et al. 2004; Sorrentino et al. 2007), pointing to an important limitation of current cell-based 
treatment approaches in these patients.  The functional deficits that cause these reduced in 
vivo activities remain to be further characterized, but likely include reduced nitric oxide 
availability and an accelerated senescence (Giannotti et al. 2010; Sorrentino et al. 2007).  
Notably, assays of a reduced functionality of bone-marrow-derived mononuclear cells, such 
as impaired migration or diminished colony formation capacity in vitro, have been associated 
with a decreased functional benefit in cell therapy trials (Assmus et al. 2007). 
 
Fetal and Umbilical Cord Blood cells may possess greater plasticity than adult progenitor 
cells because of their prenatal origin.  Umbilical cord blood contains a number of progenitor 
cell populations, including HSCs, MSCs, and unrestricted somatic stem cells, however, 
evidence of pluripotency after in vitro expansion is still lacking.  Animal studies have been 
result in an improvement in left ventricular function (Iwasaki et al. 2009; Kim et al. 2005). 
 
Resident cardiac stem and progenitor cells are a relatively rare cell population in the heart, 
which have been classified according to surface marker or transcription factor expression 
(Beltrami et al. 2003; Hierlihy et al. 2002; Oh et al. 2003).  C-Kit+ cells have the capacity for 
self-renewal, clonogenicity, and pluripotency through differentiation into myogenic, 
endothelial, and smooth muscle lineages in vitro and may contribute to repair of ischemic 
myocardium (Beltrami et al. 2003).  A second population of cardiac stem cells that express 
stem cell antigen-1 (Sca-1) have been differentiated into cells expressing cardiac specific 
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markers in vitro (Oh et al. 2003).  Furthermore, it has been demonstrated that Isl1+ cells 
display mature cardiac phenotype including expression of myocytic markers in the absence 
of cell fusion, intact calcium cycling, and generation of action potentials in co-culture 
experiments with neonatal cardiomyocytes (Laugwitz et al. 2005).  Cardiospheres, which are 
spherical clusters of cells that can be obtained with a cardiac biopsy, are plated and grown in 
culture to yield cardiosphere-derived cells in addition to other populations of resident cardiac 
progenitors (Smith et al. 2008).  A recent proof-of-concept study demonstrated that 
cardiospheres could be isolated, and expanded to provide a potentially useful population of 
autologous cardiac stem cells (Messina et al. 2004).  Several experimental studies using 
different preparations of cardiac-derived stem/progenitor cells have demonstrated positive 
effects on left ventricular function, remodeling, and infarct size; however, this has not been 
observed in all studies (Beltrami et al. 2003; Li et al. 2009; Oh et al. 2003).  In particular, no 
long-term engraftment and benefit has been observed after transplantation of Sca-1-positive 
cardiac derived stem/progenitor cells. 
 
Skeletal myoblasts transplantation into the heart as a cell-based strategy improved left 
ventricular function and reduced cardiac remodelling either to mechanical or scaffolding 
effects (Menasche 2008; Menasche et al. 2003).  Unfortunatly, skeletal myoblasts do not 
transdifferentiate into cardiomyocytes (Menasche 2008).  Remarkably, these cells lack 
electrical integrity and can therefore induce arrhythmias (Menasche et al. 2008).  Moreover 
these cells fail to show long term beneficial effects on LV-function (Menasche et al. 2008).  A 
small randomized controlled trial found that application through a 3-dimensional guided 
catheter system was favourable in terms of left ventricular function, quality of life and 
symptoms relief (Dib et al. 2009).  However, the first randomized placebo-controlled study of 
myoblast transplantation (MAGIC trial) failed to improve cardiac function as assessed by 
echocardiography (Menasche et al. 2008). 
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Embryonic stem cells are undifferentiated, pluripotent cells obtained from the inner cell mass 
of blastocysts that have the most promising potential for organ regeneration (Segers et al. 
2008; Smith 2001).  Their unlimited capacity for differentiation has garnered incremental 
interest for their use in regenerative cardiology.  Previous studies of ischemia and 
reperfusion showed improved cardiac function, directly related to paracrine effects, after 
transplantation of undifferentiated murine ESCs (Crisostomo et al. 2008; Min et al. 2003).  Of 
note, transplantation of undifferentiated murine ESCs can result in teratoma formation 
(Nussbaum et al. 2007).  The risk can be reduced by transplanting pre-differentiated ESC-
derived cardiomyocytes.  In post-infarcted rat hearts, such cells ameliorate cardiac function 
and blunt left ventricular remodeling without teratoma formation (Caspi et al. 2007; Laflamme 
et al. 2007).  Nevertheless, further investigations of tumor formation, immunologic responses 
and regenerative capacity are required to delineate the therapeutic potential of differentiated 
ESC.  Furthermore, the techniques by which ESCs are obtained have raised considerable 
social and ethical concerns, hampering the discovery process for this phenotype both in the 
preclinical and clinical arena (Murry et al. 2008; Passier et al. 2008). 
 
Induced Pluripotent Stem Cells (IPSCs) can be generated by retroviral transduction of so-
called ‘stemness’ transcription factors (Geoghegan et al. 2008; Takahashi et al. 2007; Yu et 
al. 2007).  Such cells can be maintained in culture for several months and induced to 
differentiate into lineages of all three germ layers, including cardiomyocytes, with 
electrophysiological properties and a gene expression profile that is similar to ESC-derived 
cardiomyocytes (Mauritz et al. 2008; Nelson et al. 2009).  To reduce the risk of insertional 
mutagenesis following infection with retroviral vectors, the technique has recently been 
refined to incorporate virus-free approaches for gene delivery (Okita et al. 2008).  
Furthermore, a recent study was able to generate human-induced pluripotent stem cells by 
direct delivery of reprogramming proteins without DNA vectors (Kim et al. 2009).  Also, the 
generation of functional cardiomyocytes from human induced pluripotent stem cells has been 
reported (Zhang et al. 2009).  The strategy of reprogramming somatic cells could be also 
C. Templin et al. 
 
10 
used to develop patient-specific stem cells, which could be a unique resource in studying 
genetic mechanisms of disease development, drug actions, and regenerative biology. 
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Routes of cell delivery 
 
To date several routes of cell delivery are employed, including (1) intravenous (Barbash et al. 
2003); (2) intracoronary (Strauer et al. 2002), (3) direct transepicardial (intramyocardial) 
(Perin et al. 2006) or catheter-based transendocardial (intramyocardial) injection using 
electromechanical voltage mapping (Sherman et al. 2006), and (4) a recently implemented 
approach of transvenous injection into coronary veins (Thompson et al. 2003).  Each delivery 
method has its own risks and benefits, and their suitability may also depend on the cell type 
used. 
(1) The least invasive technique is systemic intravenous infusion, which involves injecting 
progenitor cell suspensions into a vein followed by homing of the cells to the injured 
myocardium (Price et al. 2006).  The primary disadvantage of this approach is that cells may 
be trapped in the pulmonary circulation before they reach the systemic circulation (Barbash 
et al. 2003; Templin et al. 2006). 
(2) The most frequently used route of application in clinical studies is percutaneous coronary 
cell delivery.  Under these conditions, cells are injected via an over-the wire balloon catheter 
into the vessel supplying the ischemic territory.  The balloon is intermittently inflated to 
transiently stop coronary flow and allow cell distribution.  Interestingly, a recent study in the 
porcine myocardial infarction model has suggested that prolonged balloon inflation is not 
necessary for the intracoronary approach using mononuclear bone-marrow-derived cells 
(Tossios et al. 2008).  Notably, for intracoronary injection of mesenchymal stem cells in a dog 
model, however, induction of microinfarctions has been described (Vulliet et al. 2004).  In 
some studies it was observed that the percutaneous intracoronary approach showed an 
increased engraftment of transplanted MSCs in pigs after myocardial infarction as compared 
to intramyocardial injection or intravenously transplanted cells (Freyman et al. 2006) 
(Moscoso et al. 2009).  However, a recent study using bone marrow-derived mononuclear 
cells showed a 7-fold greater number of cells in the myocardium for the intramyocardial 
method and a 10-fold greater number of cells in the lungs in the intracoronary group of pigs 
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(Makela et al. 2009).  The opposing results may be related to different cell populations.  In 
any case, the intracoronary approach requires transmigration of the endothelial barrier, 
whereas after intramyocardial injection the cells are largely primarily in the interstial space. 
(3) Direct intramyocardial injections can be applied through the epicardium into the 
underlying ischemic myocardium during cardiac surgery when the heart is fully exposed.  An 
advantage of this approach is the ability to target specific areas of myocardium and scar 
under direct visualization.  In contrast, the benefit of direct intramyocardial injection may be 
limited by poor cell diffusion (Melo et al. 2004) and applications for larger areas require 
multiple injections.   
Percutaneous transendocardial delivery is performed through direct injection of cells into the 
myocardium using percutaneous catheters with small injection needles.  Electromechanical 
mapping is an excellent technique supporting the percutaneous transendocardial approach 
to identify ischemic territories (Smits et al. 2003).  Percutaneous coronary infusion and 
percutaneous transendocardial delivery are most likely more appropriate in patients without a 
planned surgical intervention.  In an experimental study, intramyocardial but not 
intracoronary injection of bone-marrow cells after myocardial infarction was associated with 
an increased risk of ventricular tachycardias (Fukushima et al. 2007).  The authors observed 
that the intramyocardial distribution of bone-marrow cells was more homogeneous after i.c. 
as compared to i.m. injection, and was associated with less inflammatory response 
(Fukushima et al. 2007). 
Therefore, the most appropriate route of cell application likely depends on the clinical setting 
(preferably i.c. in the acute myocardial infarction) and the cell type used. 
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Clinical trials 
 
Therapeutic use of bone marrow derived cells (BMCs) in the setting of acute myocardial 
infarction has been studied in more than 1000 patients worldwide.  These BMCs include 
hematopoietic and endothelial progenitor cells (approximately 2–4%), mesenchymal stem 
cells (MSC; ~ 0.1%) and a very small number of side population cells.  To date four meta- 
analyses have been published (Abdel-Latif et al. 2007; Hristov et al. 2006; Lipinski et al. 
2007; Martin-Rendon et al. 2008) suggesting the feasibility and safety of BMC application 
with a potential modest beneficial effects on left ventricular ejection fraction (LVEF) (an 
increase of approximately 3%). A reduction in ventricular volumes; a reduction in infarct or 
lesion size, ranging from 3.5% to 5.6%; and improved regional LV function (Lipinski et al. 
2007).  Although these effects on LV function are less than what was expected based on 
experimental studies in rodents, it should be noted that several of the established clinical 
therapies which do have an impact on prognosis in patients with ischemic cardiomyopathy, 
such as ACE inhibitor or beta-blocker therapy, are associated with a similarly small change in 
LV ejection fraction (Reffelmann et al. 2009).  Furthermore, a patient with the greatest 
amount of myocardial damage displayed the greatest benefit (Janssens et al. 2006).  In 
addition one study indicates that transplantation of bone marrow cells may have an impact 
on coronary flow reserve (Erbs et al. 2007).  Finally, the number of injected cells may play a 
key role for the effects on LVEF (Martin-Rendon et al. 2008).  Interestingly, the meta-
analyses suggested a trend toward a reduction in recurrent MI (Martin-Rendon et al. 2008) 
and in the REPAIR-AMI (Intracoronary Progenitor Cells in Acute Myocardial Infarction) trial of 
204 patients, even reported a significant reduction in mortality, rehospitalisation for heart 
failure, and repeated revascularization (Assmus et al. 2010; Schachinger et al. 2006).  Of 
note, the overall benefit demonstrated in the meta-analyses with regard to left ventricular 
function needs to be tempered by the results of 3 other trials (Lunde et al. 2008; Meyer et al. 
2006; Tendera et al. 2009), which demonstrated either no benefit or an initial benefit that was 
not sustained beyond 6 months.  In this regard, it has been suggested, that differences in cell 
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isolation protocols may have an impact on the functional capacity of the cells in the REPAIR-
AMI1 and ASTAMI (Autologous Stem Cell Transplantation in Acute Myocardial Infarction) 
trials and therefore may account for the discordant results.  Patients with reduced LV function 
may in fact have more benefit from BMC therapy as suggested by retrospective analyses of 
several of the above trials (Meyer et al. 2009) (Schachinger et al. 2006). 
Additionally, there are also studies using enriched CD34+ or CD133+ hematopoietic and 
endothelial progenitor cells from bone marrow or after mobilization with the cytokine G-CSF 
(Losordo et al. 2007).  Other studies used circulating blood-derived cells that have been 
isolated from mononuclear blood cells and selected ex vivo by culturing in endothelium-
specific medium for 3 days. 
The two APOLLO trials aim to evaluate whether adipose tissue-derived cells enhances heart 
function in acute or chronic ischemia (APOLLO trials). 
Further clinical trials are underway investigating the use of c-kit+ cardiac stem cells in 
patients with chronic ischemic heart disease. 
Table 1 provides an overview of current ongoing cell therapy trials in patients with myocardial 
infarction / ischemic cardiomyopathy. 
 
C. Templin et al. 
 
15 
Potential mechanisms mediating effects of adult stem/progenitor cell-based 
therapy on cardiac function 
 
There are many open questions at present with respect to the understanding of mechanisms 
of circulating or bone marrow-derived stem/progenitor cell-mediated cardiac repair (Burt et al. 
2008; Landmesser 2009; Segers et al. 2008).  Whereas initially, a rapid transdifferentiation of 
bone-marrow derived stem cells into cardiomyocytes was postulated to explain the effects on 
cardiac function (Orlic et al. 2001) several later studies have indicated that other 
mechanisms, in particular promotion of cardiac vascular growth, may mediate the observed 
beneficial effects on left ventricular (LV) function, likely at least in part due to paracrine 
effects of endothelial progenitor or bone-marrow-derived stem cells (Gnecchi et al. 2008; 
Murry et al. 2004).  This concept was further supported by the observation that circulating 
endothelial progenitor cells and bone marrow-derived stem/progenitor cells may increase 
myocardial neovascularisation and perfusion in patients (Erbs et al. 2007).  Furthermore, 
animal studies have suggested that bone marrow-derived progenitor cells (Templin et al. 
2008; Templin et al. 2006) and human endothelial progenitor cells (Kocher et al. 2001) 
improve cardiac function in rodents with myocardial infarction by promotion of 
neovascularisation and prevention of apoptosis.  It is well known from earlier studies, that 
myocardial capillary growth plays a critical role for maintenance of cardiac function (Giordano 
et al. 2001).  In addition to enhanced neovascularization, paracrine factors released by the 
incorporated cells may beneficially influence cardiac repair by protecting cardiovascular cells 
from apoptotic stimuli or even by activating cardiac-resident stem cells to enhance the 
endogenous repair capacity (Uemura et al. 2006; Urbich et al. 2005).  Paracrine mechanisms 
may additionally prevent inflammation, fibrosis and reactive hypertrophy (Burchfield et al. 
2008).  Moreover, the injection of conditioned medium in which MSCs were cultured results 
in the improvements of left ventricular function and reduced apoptosis (Gnecchi et al. 2005).  
In a further article, SFRP2 (secreted frizzled-related protein II), which modulates the Wnt 
(winglesstype MMTV integration site family) signaling system and the expression of 
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antiapoptotic genes, was shown to be the key factor released by AKT-1(v-akt murine 
thymoma viral oncogene homolog 1)–enriched MSCs (Mirotsou et al. 2007).  Recently, we 
analyzed the secreted proteome of a hematopoietic progenitor cell line which exert 
modulating effects on tissue repair and regeneration.  In this study a subset of 95 different 
proteins were identified in a mass spectrometry based approach whereas the cytokines IL-6 
and IL-13 and the chemokines MCP-1, MCP-3, MIP1-a, and MIP1-b were identified using an 
immunological approach (Luecke et al. 2010).  Furthermore, experimental data have shown 
that interleukin 10 from transplanted bone marrow mononuclear cells may contribute 
substantially to cardiac protection after MI (Burchfield et al. 2008).  Additionally, other 
cytokines and growth factors from transplanted progenitor cells may exert important 
paracrine effects like vascular endothelial growth factor, stromal cell–derived factor, 
angiopoietin 1, hepatocyte growth factor, insulinlike growth factor 1, and periostin, among 
others (Kinnaird et al. 2004; Uemura et al. 2006; Urbich et al. 2005).  Although the direct 
effects of cell therapy are not entirely understood, the majority of studies suggest that 
stem/progenitor cells may have a beneficial effect on cardiac function. 
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Limitations of current cell-based treatment approaches 
 
There is currently a limited knowledge on the role of the required number and function of 
bone marrow cells needed for an optimal effect on cardiac repair.  Low cell dosages might in 
fact limit the efficacy of bone marrow cell therapy.  For example, in the ASTAMI trial, the 
median number of mononuclear cells injected was 68 × 106, and the median number of 
CD34+ cells was 0.7 × 106.  There were no significant differences between the BMC and 
control group in changes in LVEF, end-diastolic volume, or infarct size (Lunde et al. 2006).  
In the BOOST trial, the average number of mononuclear BM cells was 24.6 x 108, and the 
number of CD34+ cells was 9.5 x 106.  Six months after randomisation, global LVEF 
increased from 50.0% to 56.7% (P=0.0026), albeit this difference was not maintained at long-
term follow-up (Wollert et al. 2004).  In the TOPCARE-AMI trial, the average number of 
mononuclear BM cells was 24.5 x 107, and the number of CD34+ cells was 7 x 106.  In 
patients receiving progenitor cells, global LVEF increased from 51.6% to 60.1% (P=0.003) 
(Schachinger et al. 2006).  To treat a patient of 80 kg with a high dose cell strategy as 
described in some animal studies (1 x 107 cells/25g) would require 32 x 109 CD34+ cells 
(adjusted to body weight), which exceeds the number of HPCs used in clinical trials by a 
factor of ~3000 (Assmus et al. 2002).  Therefore, strategies allowing rapid ex vivo progenitor 
cell expansion may improve cell-based clinical treatment regimens. 
Another potential reason for discrepancies between experimental and clinical studies with 
respect to the impact of circulating or bone marrow-derived stem/progenitor cell therapy on 
cardiac function is related to the fact, that the effect of stem/progenitor cells obtained from 
young healthy rodents in experimental studies is compared with effects of stem/progenitor 
cells obtained from older patients with chronic coronary disease in clinical studies.  In support 
of this concept, a substantially impaired in vivo vascular repair capacity of stem/progenitor 
cells derived from patients with cardiovascular risk factors as compared to healthy subjects 
has been observed (Giannotti et al. 2010; Sorrentino et al. 2007), and very recently a 
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severely reduced vascular and cardiac repair capacity of stem/progenitor cells derived from 
patients with ischemic cardiomyopathy. 
Additionally, cell therapy is currently limited by low rates of cell engraftment after 
intracoronary delivery and poor cell survival after intramyocardial injections (Hofmann et al. 
2005; Menasche 2008; Schachinger et al. 2008).  Furthermore, the amount of circulating 
progenitor cells in patients with cardiac ischemic disease comorbidities such as diabetes 
mellitus, hypertension and hypercholesterolemia is reduced (Imanishi et al. 2005; Vasa et al. 
2001).  This is problematic as this cohort is essentially the very one that would need to be 
treated with progenitor cells.  These challenges require further research to enhance the 
therapeutic efficiency of stem and progenitor cells in the treatment of ischemic heart disease.  
This includes the use of more potent cells with a higher cardiac regeneration capacity (for 
instance induced pluripotent stem cells) and strategies for improving cell homing, survival,, 
engraftment and repair capacity, of transplanted cells. 
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Future directions of cell based-therapy for ischemic heart disease 
 
The development of cell-based therapies for ischemic heart disease faces several practical 
challenges which need to be addressed.  Several studies have indicated a reduced cardiac 
and vascular repair capacity of patient-derived adult stem/progenitor cells as compared to 
cells obtained from healthy subjects (Giannotti et al. 2010; Sorrentino et al. 2007).  
Therefore, the mechanisms leading to stem/progenitor cell dysfunction need to be better 
characterized and will provide interesting novel approaches to optimize cell-based treatment 
approaches.  Moreover, strategies to improve cardiac homing and engraftment of 
stem/progenitor cells may optimize the effect the results of this treatment approach (Pons et 
al. 2008; Pons et al. 2009; Tang et al. 2009; Zhao et al. 2009). 
One interesting strategy for the improvement of current cell-based approaches may be the 
combination of cell- and gene therapy.  In this regard, we have demonstrated long-term self 
renewal and unlimited expansion of hematopoietic progenitor cells using human β-catenin 
gene transfer (Templin et al. 2008).  Administration of defined β-catenin-HPCs after MI 
reduces infarct size and improves left ventricular function and dimensions in a threshold-
dependent manner (Templin et al. 2008).  This effect is associated with improved 
angiogenesis and reduced apoptosis in the infarct border zone.  Furthermore, β-catenin-
HPCs have greater therapeutic efficacy than control-transduced HPCs (GFP-HPCs), 
demonstrating a beneficial effect of β-catenin transduction on myocardial repair (Templin et 
al. 2008).  Other recent studies have investigated specific protein expression through ex vivo 
modifications of receptors and molecules involved in progenitor cell paracrine signaling, 
homing, and survival. Numerous investigators have modified MSCs to overexpress protective 
growth factors such as VEGF (Yang et al. 2007), upregulate homing receptors (Cheng et al. 
2008), upregulate cell survival signaling pathways involving Akt (Mangi et al. 2003) and 
overexpress ischemia-protective proteins including heme oxygenase-1 (Tang et al. 2005).  
A recent interesting study combined a genetic and pharmacologic inhibition of 
dipeptidylpeptidase IV with G-CSF-mediated stem cell mobilization after myocardial infarction 
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in mice. This approach leads to increased myocardial homing of circulating CXCR-4+ stem 
cells, and improved heart function and survival (Zaruba et al. 2009). 
Pretreatment of endothelial progenitor cells with statins, eNOS-overexpression of PPAR-
gamma agonists before transfer increases their migratory, invasive, and neovascularization 
capacity - effects that are mediated by activation of endothelial nitric oxide synthase (Shao et 
al. 2008; Spyridopoulos et al. 2004).  Similary, own results showed that prestimulation of 
endothelial progenitor cells from diabetic individuals with the peroxisome proliferator 
activated receptor γ-agonist rosiglitazone, enhances nitric oxide availability and the in vivo 
endothelial repair capacity of these cells (Sorrentino et al. 2007).  MicroRNAs have been 
identified as unexpectedly potent regulators in cardiovascular biology, controlling vascular 
growth, endothelial NO synthase and stem cell differentiation and may be interesting targets 
to optimize cell-based therapies (Suarez et al. 2007; Suarez et al. 2009; van Rooij et al. 
2008). 
 
C. Templin et al. 
 
21 
Conclusion  
 
Development of cell-based strategies for cardiac repair for the use in clinical routine is an 
exciting and challenging task.  The concept of cardiac regeneration or rejuvenation and 
protection via paracrine mechanisms responses to reduce cardiomyocyte apoptosis and 
increase angiogenesis needs to be further developed and optimized, and represents one 
important line of current research.  One such approach represents the combination of cell 
and gene therapy, by either transduction of genes into stem cells or modifying stem cells as 
vectors for drug delivery.  Moreover, novel cell types with a true cardiomyocyte 
transdifferentiation potential such as iPS provide another important line in the development of 
cell-based approaches for cardiac repair.  Upscaling and safety of such an approach 
represent important challenges to be solved. 
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Figures: 
 
Fig.1. Future developments of cell-based therapy for ischemic cardiomyopathy 
(modified after Templin et al. 2010). Ex vivo modulation (e.g. microRNA modulation or 
combined gene and cell-therapy) of bone marrow derived progenitor cells may be used to 
improve current adult cell treatment strategies. Inducible pluripotent stem cells have the 
ability to differentiate into cardiovasular cells and exhibits great potential for cardiac 
regeneration. 
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